PE20181208A1 - Metodos de modulacion de moleculas de vigilancia de adn citosolicas - Google Patents

Metodos de modulacion de moleculas de vigilancia de adn citosolicas

Info

Publication number
PE20181208A1
PE20181208A1 PE2017002822A PE2017002822A PE20181208A1 PE 20181208 A1 PE20181208 A1 PE 20181208A1 PE 2017002822 A PE2017002822 A PE 2017002822A PE 2017002822 A PE2017002822 A PE 2017002822A PE 20181208 A1 PE20181208 A1 PE 20181208A1
Authority
PE
Peru
Prior art keywords
methods
modulation
cytosolic dna
molecules
dna surveillance
Prior art date
Application number
PE2017002822A
Other languages
English (en)
Inventor
Thomas Ilg
Albert Abraham
Jason Nickell
Daniel Keil
Christian Weiss
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20181208A1 publication Critical patent/PE20181208A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Abstract

Metodos para generar una respuesta inmunologica en un sujeto mediante la activacion de moleculas y vias de senalizacion de inmunidad innata especificas. En particular, se usa una composicion inmunomoduladora para estimular moleculas y vias de senalizacion de inmunidad innata.
PE2017002822A 2015-06-26 2016-06-23 Metodos de modulacion de moleculas de vigilancia de adn citosolicas PE20181208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26

Publications (1)

Publication Number Publication Date
PE20181208A1 true PE20181208A1 (es) 2018-07-23

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002822A PE20181208A1 (es) 2015-06-26 2016-06-23 Metodos de modulacion de moleculas de vigilancia de adn citosolicas

Country Status (22)

Country Link
US (1) US20190233825A1 (es)
EP (1) EP3313376A2 (es)
JP (1) JP2018518511A (es)
KR (1) KR20180021874A (es)
CN (1) CN108472255A (es)
AR (1) AR105160A1 (es)
AU (1) AU2016282879A1 (es)
BR (1) BR112017028121A2 (es)
CA (1) CA2990526A1 (es)
CL (1) CL2017003373A1 (es)
CR (1) CR20180003A (es)
DO (1) DOP2017000313A (es)
HK (1) HK1256128A1 (es)
IL (1) IL256264A (es)
MX (1) MX2017017141A (es)
PE (1) PE20181208A1 (es)
PH (1) PH12017502413A1 (es)
RU (1) RU2018102915A (es)
SG (1) SG10201913395VA (es)
TW (1) TW201710509A (es)
UY (1) UY36756A (es)
WO (1) WO2016207314A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
NZ750181A (en) 2016-07-26 2023-02-24 Bayer Animal Health Gmbh Increased fertility in bovine species
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
PT772619E (pt) * 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2002024899A2 (en) * 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
MY146351A (en) * 2003-05-29 2012-08-15 Schering Plough Ltd Compositions for treating infection in cattle and swine
DK1789559T3 (en) * 2004-08-13 2015-08-24 Univ Pennsylvania Methods to construct vaccines with no antibiotic resistance
JP2008511545A (ja) * 2004-08-13 2008-04-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失ｄｎａワクチン
DK2992899T3 (da) * 2009-05-14 2020-09-14 Bayer Ip Gmbh Forøget immunrespons hos fuglearter
CN103501810A (zh) * 2010-12-22 2014-01-08 拜耳知识产权有限责任公司 牛物种中增强的免疫应答
RU2587633C2 (ru) * 2011-05-26 2016-06-20 Интервет Интернэшнл Б.В. Иммуностимулирующие олигодезоксинуклеотиды
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
KR20160122849A (ko) * 2014-02-28 2016-10-24 바이엘 애니멀 헬스 게엠베하 면역자극성 플라스미드

Also Published As

Publication number Publication date
PH12017502413A1 (en) 2018-06-25
JP2018518511A (ja) 2018-07-12
MX2017017141A (es) 2018-03-09
CL2017003373A1 (es) 2018-06-29
AR105160A1 (es) 2017-09-13
IL256264A (en) 2018-02-28
BR112017028121A2 (pt) 2018-09-04
RU2018102915A3 (es) 2019-12-05
RU2018102915A (ru) 2019-07-29
US20190233825A1 (en) 2019-08-01
CA2990526A1 (en) 2016-12-29
UY36756A (es) 2017-01-31
WO2016207314A2 (en) 2016-12-29
EP3313376A2 (en) 2018-05-02
HK1256128A1 (zh) 2019-09-13
WO2016207314A3 (en) 2017-02-09
CR20180003A (es) 2018-03-20
SG10201913395VA (en) 2020-03-30
TW201710509A (zh) 2017-03-16
KR20180021874A (ko) 2018-03-05
AU2016282879A1 (en) 2018-01-18
CN108472255A (zh) 2018-08-31
DOP2017000313A (es) 2018-02-28

Similar Documents

Publication Publication Date Title
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
DOP2017000313A (es) Métodos de modulación de moléculas de vigilancia de adn citosólicas
MA40595A (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201691374A1 (ru) Инсулин длительного действия и его применение
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
MX2016013950A (es) Metodo para producir l-aminoacidos utilizando una bacteria alcalifilica.
ITUA20161903A1 (it) Capsula per ottenere bevande e metodo di produzione della stessa
DK3159296T3 (da) Reb til elevator og fremstillingsfremgangsmåde dertil
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
EA201591720A1 (ru) Белки, специфические по отношению к baff и b7rp1, и их применение
DK3093022T3 (da) Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma
DK3144383T3 (da) Mikroorganisme af Corynebacterium-slægten til fremstilling af L-lysin og fremgangsmåde til fremstilling af L-lysin under anvendelse af denne
BR112017012087A2 (pt) métodos de identificação de genes codificantes e não codificantes coexpressados, e sistema
EA201691203A1 (ru) Твёрдые формы тенофовира
ITUB20156002A1 (it) Composizione e metodo per trattare i nematodi
AR103281A1 (es) COMPOSICIONES, APARATOS Y MÉTODOS PARA DETERMINAR EL pH DE UNA SOLUCIÓN DE ANALITO
TH1601001388A (th) สารเพื่อลดแคแทบอลิซึมหรือกระตุ้นแอนาบอลิซึมของโปรตีน
ITUB20161195A1 (it) Metodo per aumentare il volume specifico della carta
TH1701003245A (th) วิธีของการผลิตอินเลย์เชิงหน้าที่ และอินเลย์ที่ถูกผลิตโดยวิธีนั้น
TH1601001966A (th) พอลิแกแลคโทแมนแนนซึ่งถูกแทนที่ด้วยไดไฮดรอกซิแอลคิล, และวิธีเตรียม และวิธีใช้สารเหล่านั้น